STAT+: Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readout
Tag
Pharma
Live stream
RIVO news Listen to this section's headlines in an AI voice
Now:
Press play to start the stream
This browser does not support voice playback. Try Chrome, Edge or Safari.
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks
Biotech
STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways
Here is some of what you may have missed from the world's largest cancer research meeting.
CDC is investigating a salmonella outbreak tied to moringa supplement capsules
Mogo Moringa LLC recalled 2 lots of its Pure Moringa Oleifera capsules on May 25 after 18 people across 14 states fell ill
Pharma
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Detailed study data for a pancreatic cancer treatment from Revolution Medicines confirmed it increased overall survival, from 13.2 months to 6.7 months
Biotech
STAT+: A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout
Business
STAT+: Medicare still won’t say how much covering obesity drugs will cost
Older adults on Medicare can get Wegovy and Zepbound for $50 a month, starting in July. But the agency still is not sharing how much this will cost taxpayers.
Biotech
STAT+: A standing ovation for RevMed, and caution for Akeso
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immunotherapy.
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
Biotech
STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study finds
By doing hormone therapy up front in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.
Biotech
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Biotech
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
Much-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.